MNNG-pretreatment of a human kidney carcinoma cell strain decreases its ability to repair MNNG-treated adenovirus 5.
When treated with 4-32 micro M N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), monolayers of the A498 human kidney carcinoma cell strain were less able to support plaquing by MNNG-treated adenovirus 5 than were control monolayers that received no MNNG. However, non-treated and MNNG-treated monolayers were equally able to support plaquing by adenovirus that was not treated with MNNG. Both N-ethyl-N'-nitro-N-nitroguanidine and N-methyl-N-nitrosourea (but neither u.v. nor methyl methanesulfonate) treatment of A498 monolayers caused the depressed survival of MNNG-treated adenoviruses, also indicating specificity of phenomenon. When cells infected by MNNG-treated adenovirus were treated with MNNG for 1 h as a function of post-infection time, the MNNG-depressed viral survival, observed early after infection, decreased, and was unobservable 12 h post-infection, suggesting that repair of MNNG-damaged viruses had occurred over that time period.
D000260:Adenoviruses, Human / Q000187:drug effects*; D000477:Alkylating Agents / Q000494:pharmacology; D002460:Cell Line; D003114:Colony-Forming Units Assay; D006801:Humans; D007680:Kidney Neoplasms; D007700:Kinetics; D008769:Methylnitronitrosoguanidine / Q000494:pharmacology*; D009374:Neoplasms, Experimental; D010948:Viral Plaque Assay
D000477:Alkylating Agents; D008769:Methylnitronitrosoguanidine